title: Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994.
abstract: This study was designed to evaluate drug use and drug costs of treatment of 1112 AIDS patients at the Infectious Diseases Unit at F. Houphouët Boigny Hospital in Marseilles, France, between January 1, 1990 and December 31, 1994. All drug expenditures directly or indirectly related to AIDS treatment were recorded for both inpatients and outpatients. There were 1952 hospital stays. For each stay baseline characteristics including age, sex risk factors, costs, and duration of hospitalization were noted. Patients were mainly young male drug addicts around thirty years of age. Reason for admission was also noted. The overall number of admissions per year has decreased since 1991 probably due to development of outpatient care. The number of stays per patient per year has decreased since 1993 because of the use of more appropriate therapeutic and prophylactic protocols. The number of drugs used was high increasing from 750 in 1990 to 868 in 1994. Cost of treatment doubled between 1990 and 1994 due to the introduction of many expensive new drugs. Closer analysis showed that the greatest increase in expenditure involved 'antibiotic/antiviral', 'psychiatry/neurology' and 'specialized therapy'. Although not frequently prescribed, costly drugs such as immunoglobulins, hematopoietic growth factors, and parenteral nutrition solutions accounted for a high proportion of total costs. Since AZT, ddI and ddC were used mainly for outpatient treatment, their cost was low in inpatients. Cytomegalovirus-related retinitis, tuberculosis, and multiple infections were cost-intensive complications. The increasing number of cytomegalovirus infections underlines the need for cost evaluation and surveillance of this complication. This study demonstrates that cost of treating AIDS patients is rising due to the use of more and costlier drugs. This finding underlines the need to evaluate and compare new therapeutic modalities in terms of cost effectiveness.
authors.affiliation: Department of Pharmacy, C.H.U. Nord, Marseilles, France.
authors.forename: F
authors.initials: F
authors.lastname: Peyron
authors.forename: A
authors.initials: A
authors.lastname: Flori
authors.forename: S
authors.initials: S
authors.lastname: Galliano-di Bernardo Bernardo
authors.forename: J
authors.initials: J
authors.lastname: Moreau
authors.forename: M
authors.initials: M
authors.lastname: Buès-Charbit
authors.forename: G
authors.initials: G
authors.lastname: Balansard
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D000328:Adult; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D004358:Drug Therapy / Q000191:economics; D005069:Evaluation Studies as Topic; D005260:Female; D017721:Hospital Costs / Q000706:statistics & numerical data* / Q000639:trends; D006801:Humans; D008297:Male
chemical_list: D000998:Antiviral Agents